Table 1.
Clinical and demographic characteristics of patients with systemic lupus erythematosus (SLE).
| Patient | Race | Age/sex | Disease duration (months) | Family history | ANA | Anti-dsDNA | Anti-Sm | SLEDAI | Disease manifestations | Treatments |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AA | 25/F | 48 | No | + | n.d. | + | 15 | R, HL, AR, LP, PU, LCL, IDB | Pred (40), HCQ, AZA |
| 2 | AA | 37/F | 84 | Yes | + | + | + | 12 | R, AR, PU, LCL, IDB | Pred (20), HCQ, MPA |
| 3 | AA | 45/F | 15 | No | − | − | − | 12 | R, AR, PU, LCL, IDB | Pred (20), HCQ, Others |
| 4 | AA | 43/F | 60 | No | + | + | + | 10 | AR, LCL, IDB | Pred (60), MPA, Others |
| 5 | AA | 41/F | 4 | No | + | + | n.d. | 9 | AR, LP, LCL, IDB | Pred (5), HCQ |
| 6 | AA | 50/F | 24 | No | + | n.d. | + | 8 | R, AR, LCL | HCQ, Others |
| 7 | H | 56/F | 24 | No | + | − | − | 8 | AR, PU, LCL | Pred, MPA, Others |
| 8 | H | 48/F | 24 | No | + | + | n.d. | 8 | AR, LCL, IDB | Pred (5), HCQ, MTX |
| 9 | AA | 44/F | 60 | No | + | + | n.d. | 6 | R, HL, IDB | HCQ, MTX |
| 10 | H | 28/F | 84 | No | + | + | n.d. | 6 | R, LCL, IDB | HCQ, Others |
| 11 | AA | 43/F | 48 | No | + | n.d. | n.d. | 6 | R, PU | Pred (10), HCQ |
| 12 | A | 40/M | 24 | No | + | − | − | 6 | AR, LCL | Pred (30), HCQ |
| 13 | H | 43/F | 36 | No | + | + | n.d. | 5 | R, LP | HCQ |
| 14 | AA | 50/F | 216 | No | + | + | n.d. | 5 | LP, LCL, IDB | Pred (5), HCQ |
| 15 | A | 40/F | 96 | No | + | + | n.d. | 5 | R, LP, LCL, IDB | Pred (5), HCQ |
| 16 | AA | 37/F | 84 | No | + | − | n.d. | 4 | R, LCL | Pred (10), HCQ, Others |
| 17 | H | 21/F | 8 | No | + | + | n.d. | 4 | LCL, IDB | Pred (5), HCQ, AZA, Others |
| 18 | C | 64/F | 24 | No | + | n.d. | n.d. | 4 | AR | None |
| 19 | H | 22/F | 120 | No | + | + | n.d. | 4 | LCL, IDB | Pred (10), HCQ, Others |
| 20 | C | 47/F | 252 | Yes | + | − | − | 4 | AR | Others |
| 21 | H | 44/F | 204 | No | + | n.d. | n.d. | 4 | None | Pred (20), HCQ |
| 22 | AA | 64/F | 12 | No | + | n.d. | n.d. | 4 | AR | Pred (5) |
| 23 | H | 44/F | 192 | Yes | + | n.d. | + | 4 | AR | None |
| 24 | AA | 40/F | 60 | No | + | n.d. | + | 4 | R | Pred (15) |
| 25 | AA | 57/F | 108 | No | + | n.d. | n.d. | 4 | AR | HCQ, Others |
| 26 | A | 42/F | 48 | No | + | + | + | 3 | LP, IDB | Pred (10), AZA |
| 27 | C | 31/F | 24 | No | + | + | n.d. | 2 | LCL | HCQ |
| 28 | AA | 37/F | 132 | No | + | − | n.d. | 2 | HL | Pred (10), HCQ |
| 29 | AA | 26/F | 84 | No | + | + | n.d. | 2 | None | Pred (5), Others |
| 30 | H | 37/F | 240 | Yes | + | + | n.d. | 2 | IDB | Pred (7·5), AZA |
| 31 | H | 63/F | 108 | No | + | + | n.d. | 2 | IDB | Pred (2·5), HCQ |
| 32 | AA | 25/F | 36 | No | + | + | n.d. | 2 | IDB | Pred (15), HCQ |
| 33 | C | 50/F | 12 | No | + | n.d. | n.d. | 1 | LP | HCQ |
| 34 | AA | 52/F | 36 | No | + | n.d. | n.d. | 1 | LP | HCQ |
| 35 | C | 22/F | 120 | No | + | − | − | 0 | None | Pred (20), HCQ, Others |
| 36 | H | 55/F | Unknown | No | + | − | − | 0 | None | Others |
| 37 | AA | 52/F | 24 | No | + | n.d. | n.d. | 0 | None | Others |
| 38 | H | 50/F | 12 | No | + | n.d. | n.d. | 0 | R | None |
| 39 | AA | 27/F | 36 | No | + | + | n.d. | 0 | None | Pred (5), HCQ |
| 40 | AA | 46/F | 240 | No | + | n.d. | n.d. | 0 | None | Pred (5), HCQ |
| 41 | AA | 43/F | 72 | No | + | − | − | 0 | None | Others |
| 42 | AA | 60/F | 48 | No | + | n.d. | + | 0 | None | HCQ |
| 43 | C | 24/F | 120 | No | + | n.d. | n.d. | 0 | None | Pred (20), HCQ |
| 44 | C | 35/F | 48 | Yes | + | + | n.d. | 0 | None | HCQ, Others |
| 45 | C | 22/M | 120 | Yes | + | + | + | 0 | R | Pred (10), HCQ, MTX |
A, Asian; AA, African American; ANA, anti-nuclear antibody; anti-dsDNA, anti-double-stranded DNA; anti-Sm, anti-Smith antigen; AR, arthritis; AZA, azathioprine; C, Caucasian; F, female; H, Hispanic; HCQ, hydroxychloroquine; HL, hair loss; IDB, increased DNA binding; LCL, low complement levels; LP, leukopenia; M, male; MPA, mycophenolic acid; MTX, methotrexate; n.d., not determined; Pred (X), prednisone (mg/day); PU, proteinuria; R, rash; SLEDAI, systemic lupus erythematosus Disease Activity Index.